Table 1—

Patient clinical characteristics

ControlEpalrestatP
n305289
Sex0.742*
    Male174 (57.0)161 (55.7)
    Female131 (43.0)128 (44.3)
Age (years)61.5 (± 9.1)61.5 (± 9.8)0.958
BMI (kg/m2)23.0 (± 3.4)23.1 (± 3.2)0.706
Type of diabetes0.299*
    Type 16 (2.0)9 (3.1)
    Type 2295 (96.7)279 (96.5)
    Other4 (1.3)1 (0.3)
Duration of diabetes (years)12.4 (± 8.0)13.3 (± 8.9)0.221
A1C (%)7.0 (± 1.0)7.1 (± 1.0)0.214
Diabetes therapy0.977
    Diet alone40 (13.1)44 (15.2)
    Oral hypoglycemic agent151 (49.5)133 (46.0)
    Insulin114 (37.4)112 (38.8)
Duration of neuropathy (years)3.1 (± 3.5)3.5 (± 4.6)0.387
Median MNCV (m/s)52.5 (± 4.9)52.1 (± 5.1)0.277
Diabetic retinopathy0.171
    No157 (51.5)135 (46.7)
    Simple82 (26.9)79 (27.3)
    Preproliferative26 (8.5)27 (9.3)
    Proliferative40 (13.1)48 (16.6)
Proteinuria0.826
    No224 (73.4)209 (72.3)
    Microalbuminuria30 (9.8)33 (11.4)
    Clinical albuminuria51 (16.7)47 (16.3)
  • Data are means ± SD or n (%).

  • *

    * P values were calculated using χ2 test,

  • two-sample t test, and

  • Mann-Whitney U test. Duration of neuropathy refers to mean patient-reported duration of neuropathy symptoms.